Nbw Capital LLC Exelixis, Inc. Transaction History

Nbw Capital LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $832,754 - $1.19 Million	-46,393 Closed	0 $0
Q1 2021 May 05, 2021	SELL	$20.53 - $25.22 $19,072 - $23,429	-929 Reduced 1.96%	46,393 $1.05 Million
Q4 2020 Feb 09, 2021	SELL	$18.39 - $24.8 $92,685 - $124,992	-5,040 Reduced 9.63%	47,322 $950,000
Q3 2020 Nov 05, 2020	SELL	$20.67 - $26.94 $8,598 - $11,207	-416 Reduced 0.79%	52,362 $1.28 Million
Q2 2020 Aug 07, 2020	SELL	$16.46 - $27.42 $266,800 - $444,450	-16,209 Reduced 23.5%	52,778 $1.25 Million
Q1 2020 May 11, 2020	SELL	$14.46 - $21.8 $53,198 - $80,202	-3,679 Reduced 5.06%	68,987 $1.19 Million
Q4 2019 Feb 18, 2020	SELL	$15.15 - $18.89 $104,792 - $130,662	-6,917 Reduced 8.69%	72,666 $1.28 Million
Q3 2019 Nov 04, 2019	SELL	$17.68 - $22.65 $48,248 - $61,811	-2,729 Reduced 3.32%	79,583 $1.41 Million
Q2 2019 Aug 05, 2019	BUY	$18.93 - $24.75 $5,167 - $6,756	273 Added 0.33%	82,312 $1.76 Million
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $543,723 - $686,867	27,741 Added 51.09%	82,039 $1.95 Million
Q4 2018 Feb 11, 2019	SELL	$13.65 - $21.8 $375,702 - $600,023	-27,524 Reduced 33.64%	54,298 $1.07 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $322,256 - $454,854	20,306 Added 33.01%	81,822 $1.45 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $19,840 - $23,999	-1,069 Reduced 1.71%	61,516 $1.32 Million
Q1 2018 May 07, 2018	SELL	$22.15 - $31.89 $56,438 - $81,255	-2,548 Reduced 3.91%	62,585 $1.39 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $1.58 Million - $2.01 Million	65,133	65,133 $0

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Nbw Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Nbw Capital LLC with notifications on news.